Zimbabwe Expedites Approval of Lenacapavir in Just 23 Days to Boost HIV Prevention Efforts
In a groundbreaking move to combat the HIV/AIDS epidemic, the Medicines Control Authority of Zimbabwe (MCAZ) has approved the long-acting HIV pre-exposure prophylaxis (PrEP) medication, Lenacapavir, in an unprecedented 23 days. This swift approval underscores Zimbabwe’s commitment to enhancing access to innovative health solutions and reinforcing its national HIV prevention strategy